p97, as in the treatment of cancer, is expected to be a potential therapeutic target for RA through the regulation of polyubiquitin turnover and cell death pathways in synovial fibroblasts, key players in the pathogenesis of RA. This evidence concerns the gene VCP and rheumatoid arthritis.